Business Wire

Forescout Expands Channel Program with New Managed Service Provider Partner Offering

Share

Forescout Technologies, the leader in automated cybersecurity, today announced the expansion of its Envision Channel Program, launching a new Managed Service Provider (MSP) Partner Program to support customers with enhanced technical and professional service capabilities.

Designed to offer Forescout’s most experienced and technically competent partners new flexible licensing options, consumption billing, and specialized resources, the MSP program expansion improves the partner-owned customer deployment and support experience. Forescout Partners, such as BT and Accenture, were instrumental in driving program enhancements to meet the increasing security challenges of their global customers.

Kevin Brown, Managing Director, Security for BT, said: “Cybersecurity is top of mind for our customers, who all want to ensure they’ve got the best protections for their most critical assets. BT has partnered with Forescout for several years, and we have more than 50 Forescout-accredited technical professionals supporting customer deployments around the world. This new program enhancement aligns with our customers’ demand for faster, more integrated solutions that tackle the changing threat landscape and enable their opportunities.”

“Forescout’s channel program has played a pivotal role in our company’s business journey. Our channel partners have helped countless enterprises around the globe obtain more visibility of their cyber assets to quickly mitigate critical risks,” said Keith Weatherford, vice president of worldwide channel sales, Forescout. “The evolving digital terrain is creating new demand to activate Forescout services and capabilities so these new initiatives will provide a seamless set of training and enablement resources to support them on this path.”

“We see this program as a great extension of the value we have been delivering to clients in partnership with Forescout,” said Jamie Bass, Managing Director, Security, Accenture. “Allowing an organization to more easily leverage Forescout’s industry leading capabilities in network visibility as a service supported by our global delivery team reduces the requirement to hire and train an organization’s own team to deploy and run the solution.”

The Forescout Envision Channel Program now encompasses:

  • Managed Services and Service Delivery Partner Program: Exclusively for partners who have demonstrated a high level of technical expertise and proficiency when deploying and supporting the Forescout platform. It provides highly qualified partners with flexible licensing and billing options in exchange for owning the customer support experience
  • Updated Partner Portal and New Forescout Academy Platform: Quick access to digitally rich learning resources and assets to demonstrate and be recognized for technical competencies across the Forescout platform and broad set of capabilities.
  • Partner Learning Journey Expansion: As part of the new direction for the Envision Channel Program, Forescout has developed an Accredited Engineer course for technical partner staff to be introduced to the Forescout Continuum Platform. Additionally, it has created the Forescout Forerunner Program which recognizes partners who accelerate onboarding and service delivery for client end-users.

With its new accreditations for partner engineer and technical support and new Managed Service Program, Forescout is recognizing and rewarding its global partner ecosystem to drive new earning opportunities and recognize the value add that they bring to the company’s success.

To learn more about Forescout’s Envision Channel Program, visit: https://www.forescout.com/resources/managed-service-provider-partner-program-overview/

About Forescout

Forescout Technologies, Inc. delivers cybersecurity automation across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types. The Forescout Continuum Platform provides 100% asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com

Managing cyber risk, together.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rebecca Cradick
Director of PR
rebecca.cradick@forescout.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p